Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine
CPT: Pharmacometrics & Systems Pharmacology · 2026-04 · 15 (4)
DOI: 10.1002/psp4.70246 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 08.04.2026. Verfasst von Lisa Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Sulfasalazine, Gastrointestinal Microbiome, Models, Biological, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The gut microbiome can contribute to drug metabolism and significantly influence pharmacokinetic (PK) behavior. Sulfasalazine is well‐known to be metabolized by gut bacterial azoreductases into sulfapyridine and mesalamine. Despite in vitro and in vivo evidence of the gut microbiome's role in drug metabolism, quantitative predictions of its impact on drug PK are lacking. To address this gap, we used sulfasalazine and its metabolites as a case example to build a translational modeling framework to predict the extent of gut microbiome‐mediated drug metabolism and subsequent PK of the metabolites. First, sulfasalazine conversion kinetics was measured in vitro using pooled human fecal homogenate incubation. In vitro V max was 650.5 and 200.9 pmol/min/mg feces, and K m was 3648 and 1605 μM for sulfapyridine and mesalamine formation, respectively. Based on colon and feces bacterial counts from nine healthy humans, a ratio of 0.47 was used to scale in vitro fecal V max to the colon level. Second, physiologically‐based pharmacokinetic (PBPK) models for sulfasalazine, sulfapyridine, and mesalamine were built in Simcyp and verified to predict their oral PK when dosed directly. Lastly, sulfapyridine or mesalamine PK after dosing sulfasalazine was predicted by linking the parent and metabolite PBPK models with colon luminal metabolism kinetics. The observed sulfapyridine and mesalamine PK after dosing sulfasalazine were predicted with weighted average fold‐errors of 1.21, 1.22, and 1.05 for C max , T max , and AUC, respectively. Overall, this in vitro to in vivo translation and modeling framework provides valuable insights for quantitatively predicting the in vivo impact of gut microbiome‐mediated drug metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, USA.
- Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA.
- Early Clinical Development, OMNI, Genentech, Inc., South San Francisco, California, USA.
- Envivo Bio, Inc., San Francisco, California, USA.
ORCID-Profile: Lisa Cheng
Zitieren
APA
Cheng, L., Cai, J., Auster, A., Cho, S., Keir, M., Rhee, H., Kapili, B., Shalon, D., & Ning, M. (2026). Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine. CPT: Pharmacometrics & Systems Pharmacology, 15(4). https://doi.org/10.1002/psp4.70246
Vancouver
Cheng L, Cai J, Auster A, Cho S, Keir M, Rhee H, et al. Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(4). doi:10.1002/psp4.70246
BibTeX
@article{Cheng2026,
author = {Cheng, Lisa and Cai, Jingwei and Auster, Alexis and Cho, Sungjoon and Keir, Mary and Rhee, Horace and Kapili, Bennett and Shalon, Dari and Ning, Miaoran},
title = {Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/psp4.70246}
}
EUVIMED